Priyanshu Sharma

Dr. Priyanshu Sharma

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
APAthiram Pandaram
Athiram Pandaram
JPJeyakumari Paul
Jeyakumari Paul
WWWankupar Wankhar
Wankupar Wankhar
ATAbhimanyu Thakur
Abhimanyu Thakur
SVSakshi Verma
Sakshi Verma
RRRavindran Rajan
Ravindran Rajan
Aspartame, a widely used artificial sweetener, is present in many food products and beverages worldwide. It has been linked to potential neurotoxicity and developmental defects. However, its teratogenic effect on embryonic development and the underlying potential mechanisms need to be elucidated. We investigated the concentration- and time-dependent effects of aspartame on zebrafish development and teratogenicity. We focused on the role of sirtuin 1 (SIRT1) and Forkhead-box transcription factor (FOXO), two proteins that play key roles in neurodevelopment. It was found that aspartame exposure reduced the formation of larvae and the development of cartilage in zebrafish. It also delayed post-fertilization development by altering the head length and locomotor behavior of zebrafish. RNA-sequencing-based DEG analysis showed that SIRT1 and FOXO3a are involved in neurodevelopment. In silico and in vitro analyses showed that aspartame could target and reduce the expression of SIRT1 and FOXO3a proteins in neuron cells. Additionally, aspartame triggered the reduction of autophagy flux by inhibiting the nuclear translocation of SIRT1 in neuronal cells. The findings suggest that aspartame can cause developmental defects and teratogenicity in zebrafish embryos and reduce autophagy by impairing the SIRT1/FOXO3a axis in neuron cells.


10 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
QYQiqi Yang
Qiqi Yang
YWYueyang Wang
Yueyang Wang
LSLuis A. Corchete Sanchez
Luis A. Corchete Sanchez
SMSabateeshan Mathavarajah
Sabateeshan Mathavarajah
QQQian Qin
Qian Qin
DLDavid M. Langenau
David M. Langenau
Olaparib and temozolomide (OT) combination therapy is in clinical trial evaluation for rhabdomyosarcoma (RMS). Unfortunately, OT resistance has been reported in other cancers. Using preclinical mouse xenograft experiments, we show that OT effectively suppresses RMS growth, yet over half of RMS tumors develop resistance associated with transcriptomic changes that occur in the absence of recurrent genomic mutation. Importantly, most resistant RMS models upregulate the PIK3CA/AKT pathway, activating NRF2 phosphorylation and subsequent transcriptional expression of multidrug resistance ABC transporters. PIK3CA inhibitor alpelisib re-sensitizes resistant cells to OT by suppressing expression of ABC transporters. The combination of OT + alpelisib also kills RMS cells which are resistant to standard-of-care combination chemotherapy and was effective in preclinical xenograft mouse models at curbing tumor growth. Our work defines a common resistance pathway in RMS and has credentialled PIK3CA/AKT inhibition as a preclinical strategy to kill therapy resistant RMS.

1 January 2022 in MedPulse International Journal of Anesthesiology
Verified
Journal Article
Closed access
PSPriyanshu Sharma
Priyanshu Sharma